Karen L. Bergman

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Cytyc Prenatal Products Corp. provides products for the diagnosis of pregnancy related and female reproductive disorders. The company also designs, develops, and manufactures women health care products. It was founded in 1985 and is headquartered in Sunnyvale, CA

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA.

NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY.

Precipio Diagnostics LLC operates as a cancer diagnostics reference laboratory. It offers its customers community oncologists and hospitals access to academic institutions and has combined academic-level excellence with the sales and marketing expertise, the proper operational processes and the necessary service level standards required to deliver proper support. The company was founded by Ilan Danieli in 2011 and is headquartered in New Haven, CT.

Vium, Inc. provides technology for preclinical drug discovery services. It offers biomedical investigators with technology that accelerates the preclinical drug discovery and development pipeline. The company was founded by Timothy L. Robertson and Jonathan Betts-Lacroix in 2013 and is headquartered in San Mateo, CA.

Digi-Key Corp. distributes electronic components. It also distributes semiconductors, discrete, electromechanical parts. Its products include audio products, batteries, cable assemblies, capacitors, computer & video accessories, connectors, crystals & oscillators, discrete semiconductor products and many more. The company was founded by Ronald A. Stordahl in 1972 and is headquartered in Thief River Falls, MN.

Biopartners GmbH engages in the development of biopharmaceutical products in the fields of endocrinology, multiple sclerosis, and virology. The company was founded in 2000 and is headquartered in Baar, Switzerland.

Ontario Institute for Cancer Research provides research on the prevention, early detection, diagnosis, and treatment of cancer. It offers Innovation programs, like cancer stem cell, innovation in target validation, and smarter imaging, Technology programs, like drug discovery, genome technologies, informatics and bio-computing, imaging translation, and tranformative pathology, and Translation programs. The company was founded by Calvin R. Stiller in December 2005 and is headquartered in Toronto, Canada.

Perseid Therapeutics LLC was founded in September 2009 to discover and develop novel protein pharmaceuticals utilizing Molecular BreedingTM (also commonly referred to as DNA shuffling). It seeks to develop products that deliver significant patient benefit both by improving upon known protein therapies and also by discovering new therapeutic modalities. Perseid has initially focused its efforts treating disorders through therapeutics that modulate the immune system. Perseid Therapeutics is a joint venture between Maxygen, Inc. and Astellas Pharma Inc. with Maxygen owning approximately 83%, and Astellas Pharma owning the remaining approximately 17%. As part of the joint venture arrangement, Astellas has been granted an option until September of 2012 to acquire all of Perseid ownership at pre-specified prices that increase on a quarterly basis. The launch of Perseid completed Maxygen’s multi-year strategic process whereby most of Maxygen’s assets are in arrangements under which external parties are primarily responsible for funding.

HealthTech Capital Co. invests in the healthcare sectors. It invests in capital efficient companies that use new scalable business model to improve the healthcare delivery from the hospital to the home. The company was founded by Anne DeGheest in 2010 and is headquartered in Los Altos Hills, CA.

NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland.

Elysium Therapeutics, Inc. develops pain relievers. The company was founded by Alex Gregory Sturmer and Thomas E. Jenkins in 2013 and is headquartered in Akron, OH.

Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA.

D2G Oncology, Inc. develops relating drugs to genotypes to transform precision cancer therapeutics. The company was founded by Ian Winters and Jonathan MacQuitty in 2018 and is headquartered in Mountain View, CA.

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.